click enter text
lower estim ahead earn
lower ep estimate reiter ep guid flat y/i
cc basi w/ fx impact impli ep vs current
wr/con dont see co miss given level
visibl earn expect investor focu guidanc
take closer look co initi anticip flat
ep growth appear aggress explain slide
begin pg estim core busi shrunk
see path signific improv next year howev consensu impli
core growth bp ex-mov part cost cut tax rate bonu
resumpt etc estimate tailwind instead estimate core growth
next year leav updat ep estimate
previous cc basi vs current
stock perspect expect moder thru quarter think
buy-sid expect rang next year anyth
like neg receiv anyth like engend
relief final discuss work expect
wolf hc bi-weekli webcast friday et sign
trade fundament data
upsid target
total debt total cap
float
benefit transform manag swing
factor besid total run-rat benefit
provid project ramp annual save next year
convers co suggest cost one-tim front-end load
take swift action take time yield materi
financi benefit current assum oi benefit
note everi chang translat /- swing ep
us reimburs challeng continu management indic
pharmaci reimburs pressur annual abil off-set
impli ebit net headwind believ translat
core growth neg hsd right bat pharmaci
ebit w/swing factor yoy includ potenti greater break-open gener
benefit specialti growth vs potenti moder wbad procur
save overal includ move part laid detail pg
see report ebit improv msd
well consensu project ebit flat yoy
uk retail continu struggl recent struggl uk market
primarili driven econom uncertainti impact front store sale
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
illustr page overal uk retail sale recent month show sign improv expect
busi continu see core pressur partial off-set cost save program move part
said estim significantli consensu well model ebit vs
consensu flat yoy see page
opioid exposur concern expect mount pharmaci middl on-going media scrutini
opioid partial track one case exclud pharmaci trial may proceed effici
manner possibl mean pharmaci hook track case citi huntington
cabel counti includ retail pharmaci also includ mail pharmaci see page
manufactur distributor inch closer global settlement possibl pharmaci becom center
attent track case agre pharmacist larg pharma chain less incent
fill suspici order vs independ pharmaci databas suggest opioid market share in-
line overal prescript market share also recal walgreen alreadi
settl regard investig distribut dispens oxycodon
distribut center fl six fl pharmaci note everi exposur translat npv
wba current market cap see page detail highlight wr hc technolog
distribut analyst steve baxter proprietari work opioid
page
earn april provid initi view flat ep growth anticip
growth oper capit deploy would off-set resumpt
bonu payment recal suspend bonu payment
resumpt bonu payment
on-going initi wr estimate oi ep benefit y/i
guid -msd growth impact neg
tax rate creat headwind
basi point depend year
busi headwind follow slide
reimburs pressur us pharmaci
store optim y/i oi ep benefit
integr y/i oi ep benefit
oi ep benefit y/i
run-rat save end cadenc
upsid guidanc co highlight take swift
action gener save
assum share repurchas billion per year contribut
approxim ep growth earn
long term comfort growth model deliv mid- high single-digit adjust ep growth
constant currenc one call-out fiscal anticip growth oper howev adjust ep constant
currenc expect broadli flat due reduct bonu payment
howev take closer look core growth move part co initi
anticip flat ep growth appear aggress without meaning share repo
wba flat ep guid assum growth capit deploy
base improv level core growth assumpt move part lower
ep estimate previous vs current
management indic pharmaci busi see pressur annual abl off-set
pressur impli ebit declin us retail due
possibl pressur mention could off-set vs
greater break-open gener specialti growth reflect pressur flat
earn bridg vs headwind favor non-cor move part
expect report ebit declin improv msd
 retail pharmaci ebit report adjust ebit vs growth break-down reimburs expect reimburs pressur typic year off-set suppli chain w/ comment pressur off-set growth impact reimburs similar level reimburs pressur excl lever tailwind break-open gener specialti growth growth part ebit y/yflu sale impact bp bp assum marginpart network chang script gain assum marginbonu suspens alloc retail base msd growth impact alloc us pharmacycurtail gain amend postretir gain provid co estimate invest labor initi provid co estimate save store optim estimate base convers w/ co estimate synergi save estimate base convers w/ co estimate transform manag program total w/ alloc us initi activ outsid usincrement chang non- growth non- intern growth
without notic improv uk retail market expect continu see
pressur estimate uk account intern segment rev
assum current level pressur uk market continu see
favor move part y/i like improv report ebit growth segment
-msd
key swing factor hear transform manag benefit alloc
estim benefit segment given earli action taken
uk emerg market
 ebit report ebit vs growth slight improv core growth cut under-perform storesmov part ebit y/ytemporari nh underfund higher gener impact nh underfund higher gener price unabl size itstor closur total rev assum margin strand cost store monthsfx fy guid impli total co assum one-tim ebit declin due one-tim item incl true-up loyalti account etc pharmaci fund fund next yearsdeclin uk retail say particip retail market declin calc use fs declin marginbonu suspens alloc base msd growth impact alloc estimate transform manag program total w/ alloc increment chang non- growth non- uk retail market continu struggl
accord brc-kpmg retail sale monitor uk retail sale recent month show
sign improv
on-going brexit uncertainti clearli
materi impact consum psych
one non-food categori
declin septemb consum
choos focu essenti food
one categori deliv growth
like experi increas
promot activ clear surplu stock
doesnt bear well retail desper
tri make lost ground sever
retail focu need cost
effici leanest
effici oper cope extrem
test endur octob ramp
brexit plan clearli real test
industri whole
-paul martin uk head retail kpmg
sale non-food item total growth in-stor sale non-food item s- growth wholesal growth
exclud fx contribut believ wholesal segment saw lsd earn declin
model flat core growth segment like benefit earli cost cut initi
push report ebit growth hsd
 ebit incl ebit excl report ebit vs part ebit custom contract chang revenue growth impact revenue assum impact fy guid impli total co assum wholesalebonu suspens alloc base msd growth impact alloc internationalest transform manag program total w/ alloc wholesaleincrement chang contribut ebit impli opioid mdl move track case
distributor manufactur involv track one case settl counti
involv report monday global settlement could announc soon see wr hc
technolog distribut analyst steve baxter proprietari work opioid
despit defend part settlement discuss track one case
co like seek broader settlement cover pharmaci exposur recal track
mdl expect move track bellweth trial wv date tbd
includ pharmaci like may get involv broader settlement discuss
point
pharmaci defend track case
accord titl code feder regul regist opioid manufactur distributor
dispens respons design oper system disclos registr
suspici order control substanc
track complaint also explain pharmaci duti establish polici procedur avoid
fill suspici prescript well oblig report potenti divers
titl code feder regul
secur control non-practition narcot treatment
program compound narcot treatment program
distribut control substanc person
registr know regist possess control substanc
registr shall make good faith inquiri either administr
appropri state control substanc registr agenc
determin person regist possess control
 registr shall design oper system disclos
registr suspici order control substanc registr shall
inform field divis offic administr area
suspici order discov registr suspici order
includ order unusu size order deviat substanti normal
pattern order unusu frequenc
opioid walgreen previous settl w/ opioid
recal walgreen settl doj investig
distribut dispens oxycodon distribut center fl six fl pharmaci
term agreement walgreen surrend registr temporarili
relat pharmaci distribut center
april unit state drug enforc administr serv administr inspect
warrant six walgreen retail pharmaci florida remov certain control substanc prescript
record relat document also serv inspect warrant administr
subpoena record walgreen distribut center jupit florida issu separ
administr subpoena record walgreen facil orlando florida august
june compani enter settlement memorandum agreement unit state
depart justic settl resolv administr civil matter aris
concern relat compani distribut dispens control substanc term
agreement compani paid million settlement amount surrend registr
six pharmaci florida may jupit distribut center sept
agre implement certain remedi action addit compani dismiss prejudic
petit unit state court appeal district columbia circuit
opioid difficult assess exposur pharmaci
pharmaci part recent settlement discuss difficult come
reason rang exposur
wr hc technolog distribut analyst steve baxter assum total distributor settlement
target price distributor
note everi exposur payment year would translat npv
wba current market cap
settlement discuss distributor
drugmak teva pharmaceut industri ltd said monday
offer billion treatment medic million
toward settlement lawsuit state
municip follow propos johnson johnson
billion anoth billion opioid
distributor mckesson corp inc
amerisourcebergen corp along billion
mckesson corp inc
corp propos pay billion settl claim
help fuel opioid epidem nation
associ attorney gener -- handl talk behalf
state -- counter demand
payment elig tax deduct
